To cite: Huntington S.

Weston G. Seedat F. et al.

screening strategy in the

UK: a cost-effectiveness

bmjopen-2020-038505

analysis. BMJ Open

Repeat screening for syphilis

in pregnancy as an alternative

2020;10:e038505. doi:10.1136/

Prepublication history and

paper are available online. To

view these files, please visit

org/10.1136/bmjopen-2020-

Received 16 March 2020

Revised 19 August 2020

Accepted 04 October 2020

038505).

the journal online (http://dx.doi.

additional material for this

BMJ Open Repeat screening for syphilis in pregnancy as an alternative screening strategy in the UK: a costeffectiveness analysis

Susie Huntington ^(b), ¹ Georgie Weston ^(b), ¹ Farah Seedat ^(b), ² John Marshall ^(b), ² Heather Bailey ^(b), ³ Marc Tebruegge, ^{4,5} Imtyaz Ahmed, ¹ Katy Turner ^(b), ⁶ Elisabeth Adams ^(b)

ABSTRACT

Objectives To assess the cost-effectiveness of universal repeat screening for syphilis in late pregnancy, compared with the current strategy of single screening in early pregnancy with repeat screening offered only to high-risk women.

Design A decision tree model was developed to assess the incremental costs and health benefits of the two screening strategies. The base case analysis considered short-term costs during the pregnancy and the initial weeks after delivery. Deterministic and probabilistic sensitivity analyses and scenario analyses were conducted to assess the robustness of the results.

Setting UK antenatal screening programme. Population Hypothetical cohort of pregnant women who access antenatal care and receive a syphilis screen in 1 year. Primary and secondary outcome measures The primary outcome was the cost to avoid one case of congenital syphilis (CS). Secondary outcomes were the cost to avoid one case of intrauterine fetal demise (IUFD) or neonatal death and the number of women needing to be screened/treated to avoid one case of CS, IUFD or neonatal death. The cost per quality-adjusted life year gained was assessed in scenario analyses.

Results Base case results indicated that for pregnant women in the UK (n=725 891), the repeat screening strategy would result in 5.5 fewer cases of CS (from 8.8 to 3.3), 0.1 fewer cases of neonatal death and 0.3 fewer cases of IUFD annually compared with the single screening strategy. This equates to an additional £1.8 million per case of CS prevented. When lifetime horizon was considered, the incremental cost-effectiveness ratio for the repeat screening strategy was £120 494.

Conclusions Universal repeat screening for syphilis in pregnancy is unlikely to be cost-effective in the current UK setting where syphilis prevalence is low. Repeat screening may be cost-effective in countries with a higher syphilis incidence in pregnancy, particularly if the cost per screen is low.

INTRODUCTION

Syphilis is a bacterial sexually transmitted infection (STI) caused by *Treponema pallidum* subspecies *pallidum*. The prevalence of syphilis in the UK is low, however, the number

Strengths and limitations of this study

- This is the first health economic analysis to assess the cost-effectiveness of a repeat screening strategy for syphilis in pregnancy compared with a single screen strategy within the UK setting.
- Experts provided input to inform the model parameters and validate the model structure and assumptions.
- Extensive sensitivity analyses were performed to assess uncertainty in the results.
- A lack of long-term data on the costs and utilities associated with congenital syphilis meant the focus of the analysis was on the short-term costs and health benefits, with the incremental cost-effectiveness ratio being calculated in scenario analyses.

of new diagnoses has increased over the last decade. In women, the number of cases rose from 345 in 2009 to 550 in 2018.¹

Congenital syphilis (CS) occurs via vertical transmission of syphilis during the pregnancy which can occur during any trimester and at any of the four stages of syphilis infection. The highest risk of transmission, however, occurs in primary syphilis when sores or chancres are present. Adverse pregnancy outcomes can include intrauterine fetal demise (IUFD), prematurity and neonatal death, with the risk being considerably higher in women with untreated syphilis than in pregnant women with no syphilis or in pregnant women who receive adequate treatment for syphilis following diagnosis at first trimester screening.² The risk of CS is difficult to quantify due to the small number of cases, the wide range of disease presentations and probable underdiagnosis. There is evidence, although limited, that the risk of CS is higher if women become infected while pregnant than if they have active syphilis at

employer(s)) 2020. Re-use permitted under CC BY-NC. No

C Author(s) (or their

Check for updates

commercial re-use. See rights and permissions. Published by BMJ. For numbered affiliations see

Correspondence to

end of article.

Dr Susie Huntington; susie.huntington@aquariusph. com



the time of conception.^{2 3} In infants born with CS, the infection can cause reduced growth and development, neurological impairment, bone deformities and hearing loss.^{4 5} Infants treated with intravenous benzylpenicillin sodium in the first 2 months of life are reported to have a good short-term prognosis, but long-term outcomes have not been investigated in detail.^{6 7}

In the UK, routine antenatal screening for syphilis, hepatitis B and HIV is offered to all pregnant women at their first routine antenatal appointment, usually before 12 weeks gestation, or later, for the small proportion of women who first present in their second or third trimester.^{8 9} Women who decline screening are formally reoffered and screening coverage currently exceeds 99.6%.9-11 Blood samples are initially tested using an enzyme immunoassay (EIA) with a T. pallidum particle agglutination assay (TPPA) performed on the same specimen to confirm a positive result. Women with a positive TPPA result are referred to a sexual health clinic to assess whether they have an active infection which requires treatment or a previous infection not requiring treatment. It is possible that women who screen negative for syphilis become positive later in pregnancy, either because they become infected with syphilis, or because their infection was too recent for a detectable antibody response to have been mounted at the time of the first screen. Management guidelines, outside the national screening programme, recommend that women are offered repeat testing for syphilis in late pregnancy if they have been diagnosed and treated for syphilis in the first trimester, if they consider themselves to be at risk of infection, or have a single 'high-risk' exposure.^{11 12} Assessing women's risk can be problematic and risk can change during pregnancy. Data on coverage of repeat testing or management is not routinely collected. In 2011-2013, the Surveillance of Antenatal Syphilis Screening (SASS) study was conducted to provide quantitative data on the performance of the screening pathway.¹³

Syphilis prevalence in pregnant women is low, the SASS study found that 0.04% (1/2800) of pregnant women required treatment for syphilis in 2010-2011, although the prevalence may have subsequently increased.¹³ CS incidence is also low and below the WHO elimination threshold of $\leq 0.5/1000$.¹⁴ However, between March 2016 and January 2017, four cases of CS occurred in the UK in women who screened negative for syphilis in pregnancy.¹⁵ None of whom had a repeat screen during pregnancy, and confirmatory testing later showed that they had acquired syphilis while pregnant. These infections would likely have been diagnosed and treated if repeat screening in late pregnancy was offered to all pregnant women, an approach that has not been assessed in the UK. Two models assessed the cost-effectiveness of universal repeat screening in the USA, where the prevalence of syphilis in pregnant women is higher than in the UK. One found that universal repeat screening was cost saving,¹⁶ while the other found that it cost US\$419 842 per CS case avoided.¹⁷

To inform the UK National Screening Committee (UK NSC) and in response to an increase in syphilis diagnoses in the UK and the continued occurrence of CS cases each year, although very small numbers, the clinical and cost-effectiveness of universal screening in the first and third trimesters, as an alternative strategy to universal screening in the first trimester only, was assessed.

METHODS

Model structure

A decision tree model in TreeAge (TreeAge Pro 2019, R2. TreeAge Software, Williamstown, Massachusetts, USA) was developed to assess the incremental costs and health benefits of universal repeat screening for antenatal syphilis compared with universal screening in the first trimester only (figure 1). For both screening strategies, the decision tree followed the true disease state of women and the population was split into women screened in the first/second trimester and women screened in the third trimester (ie, late presenters who would miss the opportunity for repeat screening). Women with a positive result received treatment at a sexual health clinic plus any additional testing required. Each branch (with or without syphilis) ended with the same pregnancy outcomes: IUFD or no IUFD, the latter resulting in a preterm or term delivery and either neonatal death, an infant with CS, or an infant with no CS (online supplemental figure S1).

The model included pregnant women in the UK who accessed antenatal care and received a syphilis screen in 2018 (the latest available data at the time). Pregnant women who were not screened (0.04%) were not included, since any change to the screening strategy would have no impact on their outcomes. Costs were considered from the UK healthcare system perspective. Social care costs were not included in the short term. To assess the overall impact of the two screening strategies, the costs for all pregnancy outcomes for all women screened were considered, not just costs for women with syphilis. The model threshold for early versus late first screen was 28 weeks gestation, that is, the start of the third trimester. The time horizon for the base case analysis considered short-term costs during the pregnancy and the perinatal period. Lifetime costs and utilities were not used in the base case analysis (but were considered in scenario analysis) as the data available on the long-term costs and utilities associated with CS were limited and include too much uncertainty to provide a robust result. See online supplemental table S1 for base case model assumptions.

Model parameters

Data were sought using PubMed, Google Scholar, online searches, references within papers, from experts and laboratory contacts and by data request to Public Health Agencies.




Figure 1 Overview of decision tree comparing single screening with universal repeat screening of syphilis in pregnancy. With reference to the timing of 1st syphilis screen, 'early' refers to 1st or 2nd trimester and 'late' refers to the third trimester. Where branches split, the probabilities are shown in the top branch, with # indicating (1-probability). Blue circle indicates referral to specialist management for treatment and the same seven pregnancy outcomes (as is shown in the top branch). Each branch ends with the same outcomes, but with different probabilities for each branch. Pregnancy outcomes are presented in online supplemental figure S1. FN, false negative result; FP, false positive result; PW, pregnant women; TN, true negative result; TP, true positive result.

Clinical parameters

Key clinical parameters were derived from published data and national surveillance data. Where data were only available from outside the UK, they were scaled to reflect UK pregnancy outcomes and syphilis prevalence. See table 1 for clinical parameters and methods of estimation. Furthermore, data from a large meta-analysis¹⁸ were adjusted to the UK setting to estimate the probability of each pregnancy outcome (online supplemental tables S2–S5).

Cost parameters

Cost parameters are presented in table 1. National Health Service (NHS) tariff costs or published costs from the UK were used where possible. Where no UK data were available, microcosting was used to calculate costs—informed by clinical guidelines, expert opinion and incorporating published NHS costs and tariffs where possible. To estimate the additional lifetime cost of CS, cost estimates from outside the UK were converted to pound sterling (\pounds).¹⁹ Where necessary, costs were

 Table 1
 Clinical and cost parameters for model comparing single screening with universal repeat screening of syphilis in pregnancy in the UK

	Baseline value	Low	High	Distribution	Note
Clinical parameters					
Total number of women in model (representing 1 year)	725 891	-	-	_	Based on number of deliveries in the UK in 2017/2018 and the screening uptake. See online supplemental table S6.
Probability of having syphilis at the start of pregnancy	0.00035	0.00028	0.00042	Beta	Data derived from 2011 SASS data ¹³ (England only (244/691,494)). Assume same risk in other UK countries.
Probability of becoming infected with syphilis during pregnancy	0.000017	0.0000017	0.00012	Beta	Incidence was estimated using published incidence and prevalence data from USA scaled to reflect UK prevalence. ^{13 32}
Probability of receiving syphilis screen before 28 weeks gestation	0.947	0.936	0.984	Beta	Estimate based on gestational week at first antenatal attendance. See online supplemental table S7. The low value is in line with results from SASS study. ¹³ The high value is in line with data from Northern Ireland which (from the UK countries) has the highest proportion of women attending before 28 weeks.
Probability of true positive result	0.995	0.984	1.00	Beta	Based on the average test sensitivity of five EIA assays used in the UK. High and low values are based on best and worst test performance of assays used in the UK. ^{28 29}
Probability of false negative result‡	0.005	0.016	0.00	Beta	Based on the average test sensitivity of five EIA assays used in the UK. High and low values are based on best and worst test performance of assays used in the UK. ^{28 29}
Probability of true negative result	0.998	0.999	0.99	Beta	Based on average test specificity of five EIA assays (99.8%) used in the UK. High and low are estimates. ^{28 29}
Probability of false positive result‡	0.002	0.001	0.01	Beta	Based on average test specificity of five EIA assays (99.8%) used in the UK. High and low are estimates. ^{28 29}
Cost parameters (£)					
Syphilis screen	13.36	6.68	26.72	Gamma	Estimated using microcosting. Screening is performed at the same time as other antenatal blood tests — this would also be the case for repeat screening at 28 weeks gestation. See online supplemental table S8.
Management of women diagnosed with syphilis in pregnancy	314.09	251.27	376.91	Gamma	Clinical management by sexual health clinician estimate based on London Integrated Sexual Health Tariff. ³³ See online supplemental table S9.
Intrauterine fetal demise (IUFD)*	4356.80	3485.44	5228.16	Gamma	Estimate based on 2013/2014 published estimate from UK inflated to 2017/2018 costs. ³⁴

Continued

Table 1 Continued					
	Baseline value	Low	High	Distribution	Note
Preterm delivery	7100.37	5680.30	8520.45	Gamma	Estimate based on UK costs for delivery at 32–33 weeks and 34–36 weeks gestation (inflated from 2010/2011 costs). ³⁵ UK data on gestational age at delivery (online supplemental table S10) were then used to calculate the proportion of deliveries at 32–33 (28%) and 34–36 weeks (72%).
Term delivery (37+ weeks)	2034.62	1627.69	2441.54	Gamma	Estimate based on published cost using inflated 2010/2011 UK data. ³⁵
Neonatal death†	5805.80	4644.64	6966.96	Gamma	Estimated using cost of IUFD plus additional hospital costs. See online supplemental table S11.
CS testing and treatment	6607.68	5286.14	7929.21	Gamma	Estimated using microcosting. See online supplemental tables S12 and S13.
CS neonatal screen	245.25	196.20	294.30	Gamma	Screening test for neonates born to women treated for syphilis in pregnancy. Estimated using microcosting. See online supplemental table S14.
CS lifetime healthcare cost	80 423.37	-	-	Gamma	Average additional lifetime healthcare costs attributable to CS based on cost estimate for cerebral palsy (estimate from 2000). ²²
CS lifetime health and social care cost	651 387.47	_	-	Gamma	Average additional lifetime health and social costs attributable to CS based on cost estimate for cerebral palsy (estimate from 2000). ²²

For costs, high and low values are $\pm 20\%$ of baseline values with exception of syphilis screening cost where high and low values are $\pm 50\%$.

*IUFD refers to the death of a baby in the uterus at \geq 20 weeks gestation that is, stillbirth.

†Neonatal death refers to the death of a baby within the first 28 days after birth.

‡These probabilities refer to the final diagnosis after all diagnostic testing plus discussion with sexual health consultant if diagnostic tests result is positive for treponemal antibodies.

CS, congenital syphilis; EIA, enzyme immunoassay; SASS, Surveillance of Antenatal Syphilis Screening.

inflated to 2017/2018 prices using mid-year conversion rates.²⁰

Outcomes

The primary outcome was cost to avoid one case of CS. Secondary outcomes were: cost to avoid one case of IUFD or neonatal death; the number of women who need to be screened to avoid one case of CS, IUFD or neonatal death; and the number of women who need to be treated for syphilis to avoid one case of CS, IUFD or neonatal death.

Sensitivity and scenario analyses

A univariate deterministic sensitivity analysis (DSA) was run for all probabilities and costs to determine which parameters had the greatest impact on the outcome of the model. This was done by selecting a high and low value for each input and generating outcomes. A probabilistic sensitivity analysis (PSA) using Monte-Carlo simulation (1000 iterations) was used to assess the robustness of the results and calculate 95% credibility intervals for each output using the mean and standard deviation. A beta distribution was used for clinical probability inputs, and a gamma distribution for cost inputs (table 1).

As well as the base case analysis, seven scenarios were assessed to observe how changes in model assumptions and certain parameters impacted the main outcomes:

1. Lifetime time horizon with incremental costeffectiveness ratio (ICER) in terms of cost per qualityadjusted life year (QALY) as the main outcome.

- 2. Incomplete uptake of the repeat screen—where the probability of having a second screen was 99.6%, in line with the current uptake of screening in England.
- 3. Increased syphilis incidence—varying incidence at 10 intervals between the baseline and the high value used in sensitivity analysis (0.012%).
- 4. No late presentation to antenatal care—all women are screened twice in the repeat screening strategy.
- 5. 100% sensitivity and specificity of the syphilis screening process.
- 6. 100% specificity of the repeat screen (ie, no false positives).
- Examining the per screen cost required to meet the standard National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold of £20 000-£30 000.²¹

In scenario analysis 1, the lifetime healthcare and social care costs for infants born with CS were considered. Since no data on the lifetime cost of CS were available, cerebral palsy (CP) was used as a proxy as it can also lead to a range of disabilities, vary hugely in severity, and may sometimes be a result of CS. The lifetime health and social care costs of CP were taken from a single Danish study²² adjusted to reflect UK life expectancy and gender split.

As EuroQol five-dimensions (EQ-5D) data have not been reported for CS or CP, a utility of 0.74 for infants with CS relative to a score of 1.00 for infants born with no CS was used, adapted from a 2006 study of new-born screening strategies where 0.74 was used for infants with 'mild developmental delay'.²³ These utility values were used in a similar health economic model from the USA¹⁶ and were used to calculate QALYs. In the absence of data on changes to utility for infants born with CS, it was assumed that the difference in utility between infants born with CS and infants with no CS remained constant through childhood and adulthood.

Parental HRQoLs were not considered, as this would add complexity to the model. There are no published data on many of the utility scores for each of the pregnancy outcomes, for maternal syphilis diagnosis or receiving a false negative result. These would need to be based on uncertain estimates or from expert opinion, due to limited evidence on HRQoL.

The life expectancy of infants with CS was estimated as 70 years, in line with the estimate for CP^{22} and in light of reports of CS diagnoses in a wide range of ages.²⁴ The life expectancy of infants with no CS was estimated as 81 years based on current UK data.²⁵ All costs and utilities were discounted at 3.5%, in line with NICE guidelines for England.²⁶ In DSA, discounting of utilities was varied from 0% to 6%.

Patient and public involvement

There was no patient or public involvement (PPI) in the design of the evaluation. A report outlining the model was reviewed by the UK NSC which has PPI representation and was made available for public consultation.

RESULTS

Base case analysis

The base case results indicate that in 1 year of screening pregnant women in the UK (n=725 891), the repeat screening strategy would result in 5.5 fewer cases of CS, 2 fewer cases of preterm delivery, 0.1 fewer cases of neonatal death (ie, one less neonatal death every 10 years on average), and 0.3 fewer cases of IUFD compared with the single screening strategy (table 2).

The healthcare costs would be £9 886 863 higher for the repeat screening strategy (£1 777 469 008 vs £1 787 355 870, respectively, when total annual screening costs, treatment costs and delivery costs for all pregnant women screened were considered) with most of this increase (£9 162 355) being a result of the additional screening costs (table 3).

The model calculated that 124 292 women would need to be rescreened in the third trimester to prevent one case of CS, 2.6 million to prevent one case of IUFD (ie, one case prevented approximately every 3.6 years if every pregnant woman was rescreened), and 5.5 million to prevent one case of neonatal death (ie, one case prevented approximately every 7.6 years if every pregnant woman was rescreened, table 4). It would cost an additional £1 791 880 per case of CS prevented, £37 852 707 per case of IUFD prevented and £79 507 578 per neonatal death prevented. An additional 251 women need to receive treatment for syphilis to prevent one case of CS (table 4).

Sensitivity and scenario analyses

The DSA results indicated that even accounting for parameter uncertainty, the total cost of the repeat screening strategy was always higher than the cost of the single screening strategy (see online supplemental figure S2 for Tornado diagram). Total costs were most sensitive to changes in the per screen cost, but also to changes in the specificity of the screening process, the proportion of women first attending antenatal care before their third trimester, syphilis incidence and the cost of syphilis treatment (online supplemental figure S2). In the DSA examining the impact of clinical and cost parameters on the number of CS cases, the model was most sensitive to syphilis incidence during pregnancy and the probability of CS in infants born to women infected with syphilis during pregnancy who did not receive treatment (ie, were undiagnosed; see online supplemental figure S3). In all iterations in the 1000 PSA Monte Carlo simulations, the repeat screening strategy cost more than the single screening strategy and resulted in fewer cases of CS. The incremental cost and incremental cases of CS prevented are shown in online supplemental figure S4.

When lifetime costs and utilities were considered (scenario 1), the health and social care cost per additional QALY gained for the repeat screening strategy (ICER) was £120 494. In DSA, the ICER was £32 716 and £205 600, when discounting of utilities was 0% and 6%, respectively (see online supplemental table S15). Even if

ล

		Women	False positive	Intrauterine	-	Neonatal	
Screening strategy	Syphilis antenatal screens	treated for syphilis	maternal syphilis	tetal demise (all causes)*	tetal demise (all Preterm deliveries deaths (all causes)* (all causes)* causes)*	deaths (all causes)*	Congenital syphilis cases
Existing: single screen							
Estimate	725 891	1705	1451	2904.4	54 228	1446.5	8.8
95% CI†	725 891 to 725 891	1698 to 1737	1443 to 1482	2890 to 2916	53 905 to 54 282	1441 to 1457	8.7 to 8.9
Alternative: repeat screen							
Estimate	1 411 696	3089	2823	2904.1	54 226	1446.4	3.3
95% CI†	1 411 456 to 1 411 503	3074 to 3150	2806 to 2883	2889 to 2915	53 903 to 54 280	1441 to 1457	3.3 to 3.3
Difference	685 805	1384	1372	-0.3	-2	-0.1	-5.5
*These adverse pregnancy outcomes are all-cause outcomes for all 725 891 women screened, including the small number with syphilis infection. †95% confidence interval, calculated using probabilistic sensitivity analysis.	are all-cause outcomes for all 725 using probabilistic sensitivity analy	891 women screen /sis.	ied, including the sm	all number with syph	ilis infection.		

a lower discounting rate were considered by NICE in the future, it is unlikely that 0% discounting would be used.

In further scenario analyses, reducing the uptake of repeat testing to 99.6% (in line with current uptake of the first screen, Scenario 2), including all women who attended antenatal care before their third trimester (ie, no late first screen, scenario 4), including 100% sensitivity and specificity of the screening process (scenario 5), or including no false positives in the second screen (scenario 6) had very little impact on the model outcomes, reducing the base case cost per CS case avoided by <10% (data not shown).

When the probability of becoming infected with syphilis between screens was increased sevenfold to 0.00012 (scenario 3), repeat screening resulted in 39 fewer cases of CS compared with single screening, 0.9 fewer neonatal deaths, 13 fewer preterm deliveries, and 1.8 fewer cases of IUFDs while the repeat strategy cost an additional £9 638 476 (online supplemental tables S16 and S17). In this scenario, the cost per CS case prevented was £247 284 (online supplemental table S18). Online supplemental table S19 in the online supplement presents the cost per case of CS avoided and the ICER when the probability of becoming infected with syphilis between screens is higher than baseline (at 10 intervals between 0.00003 and 0.00012). As anticipated, with each increase in incidence, the repeat screening strategy resulted in more CS cases prevented and a lower cost per CS case prevented. When lifetime healthcare and social-care costs were considered, the ICER was £11 171 (below the £20-£30k threshold used by NICE), when syphilis incidence in pregnancy was 0.004% and became cost saving at an incidence of 0.005%(1 in 100 000) or higher.

Scenario 7 examined the cost per screen needed to meet NICE ICER thresholds (at the current syphilis incidence) (see online supplemental table 20). The per screen cost would need to decrease from £13.36 to £6.46 to take the ICER below £30k and £5.70 to take it below £20k when lifetime health and social care costs and utilities of CS were considered.

DISCUSSION

We report on the cost-effectiveness of repeat universal syphilis antenatal screening in the UK. Our results indicate that this screening strategy would not be costeffective in the current UK setting where the prevalence and incidence of syphilis among pregnant women is low. Although the repeat screening strategy is likely to result in fewer cases of CS, the number of cases prevented would be small, 5–6 a year, and would cost an additional £9.9 million, equivalent to £1.8 million per case prevented. Most of the increase in cost is a result of the additional costs related to providing the second screen rather than treatment or delivery costs for women with syphilis.

The PSA and DSA indicated that the model results are robust to changes in the inputs. When lifetime health and social care costs and health-related quality of life
 Table 3
 Base case short-term annual healthcare costs from model comparing universal repeat screening of syphilis in late pregnancy with single screening

		Cost breakdown*		
Screening strategy	Total healthcare costs	Antenatal syphilis screening	Syphilis treatment (in pregnant women found positive)	Perinatal costs (for all pregnancies)
Existing: single screen				
Estimate	£1 777 469 008	£9 697 904	£535 434	£1 767 235 670
Lower 95% Cl Upper 95% Cl	£1 769 393 140 £1 778 772 048	£9 661 636 £9 822 870	£532 820 £545 591	£1 759 111 560 £1 768 490 710
Alternative: repeat screen				
Estimate	£1 787 355 870	£18 860 259	£970 254	£1 767 525 357
Lower 95% Cl Upper 95% Cl	£1 779 322 118 £1 788 703 813	£18 786 836 £19 100 346	£964 636 £989 342	£1 759 402 583 £1 768 782 187
Cost difference	£9 886 863	£9 162 355	£434 820	£289 687

*Costs to the NHS in the UK for all 725 891 pregnant women screened. Costs are spilt into (1) antenatal screening costs, which includes sample collection and laboratory testing; (2) syphilis treatment within sexual health clinics and (3) perinatal costs, which includes the costs of delivery and neonatal care for all infants.

NHS, National Health Service.

(HRQoL) were considered (Scenario 1), the cost per QALY gained was £120 494 for the repeat screening strategy compared with the single screening strategy. This is well above the £20k–£30k cost per QALY threshold that NICE uses to assess interventions,²¹ and also exceeds the £100 000 threshold used to assess drugs/interventions for rare conditions (the threshold used when the intervention results in <10 additional QALYs to an individual in their lifetime).²⁷ For this analysis, costs and utilities were discounted by 3.5%, in line with NICE guidelines for England.²⁶ When no discounting of utilities was assessed in DSA, the cost per QALY gained was £32 716, just above the £30k threshold.

Only two previous economic evaluations have assessed universal repeat syphilis screening in pregnancy compared with single screening in early pregnancy, both in the USA. Albright *et al* reported that repeat thirdtrimester screening would prevent 60 CS cases per 4 million women costing US\$419 842 per case avoided, concluding that repeat screening was not cost-effective.¹⁷ Hersh *et al* found that repeat screening would prevent 41 CS cases per 3.9 million women and result in total cost savings of US\$52 million.¹⁶ Neither study accounted for late presentation to antenatal care—syphilis prevalence and incidence were considerably higher than in the UK as were healthcare costs.

It is important to note that changes to the screening strategy would not change the number of adverse pregnancy outcomes in women who decline screening, in women who present late to antenatal care and have one screen but no opportunity for a repeat screen, or in women who first present at the time of delivery, thereby missing the opportunity for any antenatal screening or treatment. For this reason, and because treatment for syphilis is not universally effective at preventing adverse pregnancy outcomes, it is likely that there would continue to be a very small number of infants born with CS each year irrespective of changes made to the screening strategy.

Strengths and weaknesses

This is the first health economic analysis to assess the costs and clinical benefits of a repeat screening strategy for syphilis compared with a single screen strategy within the UK setting. The input values in the model were based on the best available evidence from the published literature,

 Table 4
 Requirements to prevent one outcome – from model comparing universal repeat screening of syphilis in late

 pregnancy with single screening

Outcome	Cost	Women screened in third trimester	Women treated for syphilis—TP and FP	Additional false positives
Congenital syphilis	£1 791 880	124 294	251	249
Intrauterine fetal demise	£37 852 707	2 625 664	5300	5251
Neonatal death	£79 507 578	5 515 066	11 133	11 030

FP, false positive; TP, true positive.

UK-specific surveillance data, NHS tariffs and published costs, and with input from experts in the field where data were lacking. These inputs were rigorously tested in sensitivity and scenario analyses to add confidence to the results, despite limited data in some areas.

There were sparse UK data available on pregnancy outcomes in women treated for syphilis or in infants born with CS. There are no published EQ-5D scores for CS and a lack of evidence on changes to utility and health and social care costs over time for infants born with CS. We therefore used the additional lifetime cost of CP, estimated in a study from Denmark,²² as a proxy for the lifetime cost of CS. As such, the primary focus of the analysis was the short-term costs and CS cases avoided since it was difficult to have confidence in the estimate used for lifetime CS cost or utility.

The model assumed that women could not become infected with syphilis between the repeat screen and delivery. As the incidence estimate relates to the full duration of pregnancy, this assumption would overestimate the number of women diagnosed and treated at the repeat screen, thereby overestimating the benefits of the repeat screen strategy. However, the number of women who become infected with syphilis during pregnancy is small and as such this would have little impact on the overall results. Since we do not know what repeat screening coverage would be, the model assumed 100% coverage, since all women in the model had already agreed to a first screen. This is optimistic, since it assumes continued engagement with antenatal services. However, scenario analysis 2 showed that even when uptake was <100% it would be unlikely to have much impact on the cost per CS case avoided.

It was also assumed that all women and neonates diagnosed with syphilis receive the appropriate full course of treatment and all infants born to women diagnosed with syphilis in pregnancy receive syphilis testing at birth. However, the SASS study¹³ found that in 2010–2011, not all women diagnosed with syphilis received complete treatment and inadequate paediatric follow-up was identified as an issue. Lack of treatment in these women and neonates is likely to make the repeat screening even less cost-effective.

Since there are no published estimates of the diagnostic accuracy (DA) of the syphilis screening process, accounting for the DA of laboratory assays and the diagnosis decision making by clinicians, average sensitivity and specificity of EIA assays used in UK laboratories were used.²⁸ The DA values used here are considerably higher than those used in the US models,^{16 17} where a different testing algorithm is used²⁹ and would, if anything, bias repeat screening results towards being more cost-effective.

Implications for clinicians and policy-makers

The number of CS cases was most sensitivity to changes in the syphilis incidence between screens. It may be costeffective to repeat screen for a period of time where there is a known syphilis outbreak or if there are multiple cases of CS in a short period within the same geographical area in women who tested negative for syphilis at the first screen—as this would indicate a much higher syphilis incidence in pregnancy in that area.

Our model focused on the UK but is relevant to other European countries with similar syphilis prevalence and healthcare costs. Our analyses, using UK cost estimates, suggest that a universal second screen in late pregnancy could become cost-effective if the incidence of syphilis in pregnancy were to increase (to 5 per 100 000 pregnant women), indicating that in countries that have far higher syphilis prevalence than the UK, a second screen could be cost saving. For example, recent estimates suggest that the prevalence of syphilis in the WHO African region is more than 10-fold higher than in the WHO European Region.³⁰ In such a high prevalence setting, combined with lower local healthcare costs, a second syphilis screen in late pregnancy could be cost-effective.

There could be some negative impact associated with repeat screening. A false positive result may lead to additional costs, unnecessary anxiety for mothers and their families, impact the mother's relationships, possibly even damage their confidence in the screening programme, as well as lead to overtreatment. It is vital to minimise unnecessary use of antibiotics where possible given growing concerns around antimicrobial resistance and because there is some evidence that antibiotic use in pregnancy increases the risk of childhood epilepsy, obesity and asthma.³¹

Alternative approaches to reduce the number of CS cases and other adverse pregnancy outcomes could be more cost-effective and should be explored. These include better targeting of high-risk individuals and sexual health promotion in pregnancy. Furthermore, of the 20 CS cases in the UK since 2010, 11 had no record of the mother receiving antenatal screening. It remains unknown whether this was because testing was refused or due to very late/no first antenatal attendance.¹⁵ This highlights the need to ensure timely screening in pregnancy, particularly in women who present late who are already at increased risk of adverse pregnancy outcomes. Education for pregnant women around sexual health and STI prevention might be cost-effective and could be considered.

Unanswered questions and future research

Our model had a single disease focus. At present, however, pregnant women are screened for syphilis, HIV and hepatitis B. It would be useful to assess the potential cost-effectiveness of a repeat screen for all three infections since treatment for these infections during late pregnancy and/or at birth would reduce the risk of vertical transmission. Screening for all three infections may yield more benefits in terms of clinical outcomes and may make this strategy more cost-effective.

Furthermore, data collection including gestational week of first screen, coverage of repeat screen in highrisk women, pregnancy outcome for women treated for

CONCLUSIONS

The results of this health economic analysis indicate that implementing universal repeat screening for syphilis in pregnancy is unlikely to be cost-effective in the current UK setting where the prevalence and incidence of syphilis in pregnant women is low. Repeat screening could be considered in areas with a high syphilis incidence in pregnancy and may then be cost-effective, particularly if the cost per screen is low.

If syphilis prevalence continues to increase, the costeffectiveness of the repeat screening strategy should be re-examined, highlighting the importance of continued monitoring of syphilis in pregnant women, screening uptake, CS cases and long-term follow-up.

Author affiliations

¹Aquarius Population Health Ltd, London, UK

- ²UK National Screening Committee, Public Health England, London, UK
- ³UCL Institute for Global Health, University College London, London, UK
- ⁴Department of Paediatric Infectious Diseases & Immunology, Evelina London Children's Hospital, London, UK
- ⁵Department of Paediatrics, The Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia

⁶School of Veterinary Science, University of Bristol, Bristol, UK

Twitter Susie Huntington @AquariusPH, Katy Turner @katymeturner and Elisabeth Adams @aquariusph

Acknowledgements We would also like to thank the following people for their contributions to this work: Nicola Bowers, Helen Fifer, Lyn Hutchison, Margaret Kingston, Anne Mackie, Paddy McMaster, Catherine Peckham, Ian Simms, Judith Timms and Sharon Webb.

Contributors The model structure was developed by SH, with input from GW, FS and JM. The final model structure was informed by input from JM, HB, MT, IA, KT and EA. SH developed the model parameters with input from MT, IA, GW, HB, FS, JM and KT. SH drafted the paper. All authors contributed to the interpretation of the results and contributed to the contents of the paper. All authors have approved the final submitted version.

Funding Award/Grant number is not applicable.

Competing interests SH, GW and EA work at Aquarius Population Health and have received consultancy fees from the following companies on projects related to STIs: Abbott, Cepheid, Binx Health, Hologic and St. Georges University of London. IA, KT and MT were funded as consultants on the project through Aquarius Population Health. MT has received support from Cepheid for conference attendance. KT is in receipt of funding to University of Bristol from GlaxoSmithKline for work unrelated to this work.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines,

terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Susie Huntington http://orcid.org/0000-0002-2854-7441 Georgie Weston http://orcid.org/0000-0003-3019-7150 Farah Seedat http://orcid.org/0000-0002-3563-7875 John Marshall http://orcid.org/0000-0002-6239-774X Heather Bailey http://orcid.org/0000-0003-3266-1041 Katy Turner http://orcid.org/0000-0002-8152-6017 Elisabeth Adams http://orcid.org/0000-0002-4222-9394

REFERENCES

- 1 Public Health England. Sexually transmitted infections (STIs): Annual Data Tables 2014-2018, 2019. Available: https://www.gov.uk/ government/statistics/sexually-transmitted-infections-stis-annual-data-tables
- 2 Ricci JM, Fojaco RM, O'Sullivan MJ. Congenital syphilis: the University of Miami/Jackson Memorial medical center experience, 1986-1988. *Obstet Gynecol* 1989;74:687–93.
- 3 Sheffield JS, Sánchez PJ, Morris G, et al. Congenital syphilis after maternal treatment for syphilis during pregnancy. Am J Obstet Gynecol 2002;186:569–73.
- 4 Gomez GB, Kamb ML, Newman LM, *et al*. Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis. *Bull World Health Organ* 2013;91:217–26.
- 5 De Santis M, De Luca C, Mappa I, et al. Syphilis infection during pregnancy: fetal risks and clinical management. Infect Dis Obstet Gynecol 2012;2012:1–5.
- 6 Mwaniki MK, Atieno M, Lawn JE, et al. Long-Term neurodevelopmental outcomes after intrauterine and neonatal insults: a systematic review. *The Lancet* 2012;379:445–52.
- 7 Arrold SR, Ford-Jones EL. Congenital syphilis: a guide to diagnosis and management. *Paediatr Child Health* 2000;5:463–9.
- 8 NHS Digital. NHS Maternity Statistics, England 2017-18, 2018. Available: https://digital.nhs.uk/data-and-information/publications/ statistical/nhs-maternity-statistics/2017-18 [Accessed 19 Jun 2019].
- 9 PHE and NHS. NHS Infectious Diseases in Pregnancy Screening Programme Screening Standards Data Report 1 April 2016 to 31 March 2017, 2019. Available: https://www.gov.uk/government/ publications/infectious-diseases-in-pregnancy-screening-standardsdata-report [Accessed 21 May 2019].
- 10 Public Health Agency, Belfast. Sexually transmitted infection surveillance in Northern Ireland. An analysis of data for the calendar year 2016, 2017. Available: https://www.gov.uk/government/ statistics/sexually-transmitted-infections-stis-annual-data-tables
- 11 Public Health England. NHS Infectious Diseases in Pregnancy Screening Programme Handbook 2016 to 2017, 2016. Available: https://www.gov.uk/government/publications/infectious-diseases-inpregnancy-screening-programme-handbook
- 12 Public Health England. Screening tests for you and your baby. Important information about the screening choices you will have during and after your pregnancy. NHS booklet, 2020. Available: https://assets.publishing.service.gov.uk/government/uploads/ system/uploads/attachment_data/file/865122/Screening_tests_for_ you_and_your_baby_information_leaflet.pdf
- 13 Townsend CL, Francis K, Peckham CS, et al. Syphilis screening in pregnancy in the United Kingdom, 2010-2011: a national surveillance study. BJOG: Int J Obstet Gy 2017;124:79–86.
- 14 World Health Organization. Global guidance on criteria and processes for validation: elimination of mother-to-child transmission (EMTCT) of HIV and syphilis. Geneva World Health Organization; 2013. https://www.who.int/reproductivehealth/publications/emtcthiv-syphilis/en/
- 15 Furegato M, Fifer H, Mohammed H, *et al.* Factors associated with four atypical cases of congenital syphilis in England, 2016 to 2017: an ecological analysis. 2017;22.
- 16 Hersh AR, Megli CJ, Caughey AB. Repeat screening for syphilis in the third trimester of pregnancy: a cost-effectiveness analysis. *Obstet Gynecol* 2018;132:699–707.

Open access

- 17 Albright CM, Emerson JB, Werner EF, et al. Third-Trimester prenatal syphilis screening: a cost-effectiveness analysis. Obstet Gynecol 2015;126:479–85.
- 18 Qin J, Yang T, Xiao S, et al. Reported estimates of adverse pregnancy outcomes among women with and without syphilis: a systematic review and meta-analysis. *PLoS One* 2014;9:e102203.
- 19 XE Currency Converter. Available: https://www.xe.com/
- 20 Curtis L, Burns A. Unit costs of health and social care 2018, personal social services research unit, University of Kent, Canterbury, 2018. Available: https://www.pssru.ac.uk/project-pages/unit-costs/unitcosts-2018/
- 21 National Institute for Clinical Excellence. Guide to the methods of technology appraisal 2013, 2013. Available: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781
- 22 Kruse M, Michelsen SI, Flachs EM, et al. Lifetime costs of cerebral palsy. *Dev Med Child Neurol* 2009;51:622–8.
- 23 Carroll AE, Downs SM. Comprehensive cost-utility analysis of newborn screening strategies. *Pediatrics* 2006;117:S287–95.
- 24 Probst LE, Wilkinson J, Nichols BD. Diagnosis of congenital syphilis in adults presenting with interstitial keratitis. *Can J Ophthalmol* 1994;29:77–80.
- 25 Office for National Statistics. National Life Tables, UK: 2016 2018, 2019. Available: https://www.ons.gov.uk/peoplepopulationandc ommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/nati onallifetablesunitedkingdom/2016to2018 [Accessed 1 Oct 2019].
- 26 National Institute for Health and Care Excellence. How should NICE assess future costs and health benefits. NICE citizens Council

meeting, 2020. Available: https://www.nice.org.uk/Media/Default/ Get-involved/Citizens-Council/Reports/CCReport15Discounting. pdf

- 27 Powell T, O'Donnell M. House of commons debate pack. NICE appraisals of rare diseases, 2019. Available: http://researchbriefings. files.parliament.uk/documents/CDP-2019-0022/CDP-2019-0022.pdf
- 28 Public Health England. Data on EIA assays used in UK supplied by lead microbiologist for bacterial STIs at the National infection service; 2019.
- 29 Morshed MG, Singh AE. Recent trends in the serologic diagnosis of syphilis. *Clin Vaccine Immunol* 2015;22:137–47.
- 30 Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ 2019;97:548–62.
- 31 Kuperman AA, Koren O. Antibiotic use during pregnancy: how bad is it? *BMC Med* 2016;14.
- 32 Shiber L, Todia WJ. Cost and clinical utility of repeated syphilis screening in the third trimester in a high-risk population. *Am J Obstet Gynecol* 2014;210:267.e1–267.e5.
- 33 Pathway Analytics. Integrated Sexual Health Tariff London ISHT 2017/2018. Available: https://www.pathwayanalytics.com/
- 34 Campbell HE, Kurinczuk JJ, Heazell A, et al. Healthcare and wider societal implications of stillbirth: a population-based cost-of-illness study. BJOG 2018;125:108–17.
- 35 Khan KA, Petrou S, Dritsaki M, et al. Economic costs associated with moderate and late preterm birth: a prospective population-based study. BJOG: Int J Obstet Gy 2015;122:1495–505.

Online Supplement


Contents

Figure S1.	Pregnancy outcomes used in the decision tree comparing universal repeat
	screening of syphilis in late pregnancy with single screening
Figure S2.	Tornado diagram – one-way deterministic sensitivity analysis of total costs -
	parameters with least impact removed4
Figure S3.	Tornado diagram - one-way deterministic sensitivity analysis of CS cases -
	parameters with least impact removed5
Figure S4.	Incremental cost versus additional cases of CS prevented6
Table S1.	Assumptions applied to screening strategies and rationale7
Table S2.	Pregnancy outcomes - parameter inputs for decision tree comparing universal
	repeat screening of syphilis in late pregnancy with single screening8
Table S3.	Pregnancy outcome data taken from published large meta-analysis of
	international studies [2]10
Table S4.	Comparing the risk of adverse pregnancy outcomes in meta-analysis with risk
	observed in the UK in order to scale meta-analysis data12
Table S5.	Pregnancy outcome data used in the model – adjusted from published large
	meta-analysis of international studies [2] to reflect UK risks13
Table S6.	Overall number of women screened for syphilis in pregnancy, 2017/1814
Table S7.	Gestational week at first antenatal care attendance – by UK country15
Table S8.	Calculating the cost per antenatal syphilis screen16
Table S9.	Calculating the cost of treatment and management of women diagnosed
	with syphilis in pregnancy
Table S10.	Gestational week at delivery (used for calculating delivery costs and estimating
	pregnancy outcomes)
Table S11.	Calculating the average healthcare costs associated with a neonatal death20
Table S12.	Calculating the cost of testing for syphilis in neonates with clinical signs of
	congenital syphilis (CS)
Table S13.	Calculating the cost of treating neonates with congenital syphilis (CS)23

1

Table S14.	Calculating the cost of neonate screening in infants born to mothers treated
	for syphilis in pregnancy24
Table S15.	Long-term health care and social care costs associated with congenital
	syphilis (CS) – results of the model comparing universal repeat screening
	of syphilis in late pregnancy with single screening25
Table S16.	Clinical outcomes for Scenario 3 (0.00012 probability of syphilis infection
	in pregnancy)
Table S17.	Cost outcomes for Scenario 3 (0.00012 probability of syphilis infection
	in pregnancy)26
Table S18.	Requirements to prevent one outcome for Scenario 3 (0.00012 probability
	of syphilis infection in pregnancy)
Table S19.	Short and long-term cost outcomes for Scenario 3 (higher syphilis incidence
	in pregnancy)27
Table S20.	Cost per screen needed to meet NICE ICER thresholds (Scenario 7)29
References	

Figure S1. Pregnancy outcomes used in the decision tree comparing universal repeat screening of syphilis in late pregnancy with single screening



Footnote:

IUFD, intrauterine fetal demise; preterm refers to <37 weeks gestation. The blue triangle indicates the branch end point.

This diagram complements **Figure 1** in the main body of the paper. The probability of each of these outcomes occurring for each branch of the tree is presented in **Table S2**.

Figure S2. Tornado diagram – one-way deterministic sensitivity analysis of total costs - parameters with least impact removed


Cost of syphilis screening including sample collection and pathology	5,305,685	19,049,218
Probability of positive result in women with no syphilis	9,513,802	13,743
Probability of first screen in 1st/2nd trimester (<28 weeks)	9,779,232 10,265,938	
Probability of becoming infected with syphilis during pregnancy (i.e. incidence)	9,638,476 9,923,759	
Cost of antenatal syphilis treatment and management	9,799,896 9,973,830	
Cost of testing neonates of mums treated for syphilis in pregnancy	9,819,377	
Probability of CS in women infected with syphilis in pregnancy - but not treated	9,868,236 9,905,489	
Cost of tests and hospital care for neonates & infants with CS	9,879,571 9,894,154	
Probability of preterm delivery in women infected with syphilis in pregnancy but not treated	9,883,207 9,889,890	
Cost of preterm delivery	9,884,072 9,889,653	
Probability of preterm delivery in women infected with syphilis in pregnancy and treated in 3rd trimester	9,884,935 9,890,134	
3.9	5.9 7.9 9.9 11.9 13	8.9 15.9 17.9

■Low ■High


Note: £9,886,863 is the baseline difference in costs. CS, congenital syphilis.


Difference in cost (£m)

Figure S3. Tornado diagram - one-way deterministic sensitivity analysis of CS cases - parameters with least impact removed



Low ■ High





This figure is an output from the Probabilistic Sensitivity Analysis (PSA) and shows the impact of parameter uncertainty on the cost per additional case of CS prevented in universal repeat screening of syphilis in late pregnancy versus single screening.

Table S1. Assumptions applied to screening strategies and rationale

Assumption	Note
All women found positive for syphilis, at their first or repeat screen, are referred to care within a sexual health clinic and are successfully treated within that setting.	As per clinical guidelines [1]. Uptake of treatment in diagnosed women is thought to be high. No published data were found to support or refute this assumption.
The clinical management of women who are diagnosed with syphilis at their first screen includes repeat testing of syphilis and as such they do not receive a repeat screen as part of the IDPS in either screening strategy.	Recommendation from experts. This is hypothetical, as repeat screening is not current practice.
Infants born with CS display signs of CS, 40% at birth and 60% some weeks/months after delivery and are tested and treated accordingly.	Based on expert opinion and evidence indicating that most infants with CS develop signs by 5 weeks. Lack of data on the proportion of CS cases with late presentation (after two years) [1].
There is no loss to follow-up, i.e. all women who are identified as needing treatment receive it.	Inclusion of loss to follow-up in the model would add unnecessary complexity to the model. Also, there is lack of data on loss to follow-up in this setting.
There is 100% uptake of repeat screening in women who were initially screened.	Assessed in Scenario Analysis 2.
The model inputs are not correlated.	To avoid over complexity in the model and due to lack of evidence around correlation.
Pregnant women who attend first antenatal care late receive their first screen at that point and therefore miss the opportunity for a repeat test.	Recommendation from experts. This is hypothetical, as repeat screening is not current practice.
Preterm vs. term delivery impacts costs but the model assumes it has no impact on the risk of pregnancy outcomes (neonatal death or congenital syphilis).	Lack of data around correlation between timing of delivery and pregnancy outcome.
The repeat screen would be performed at 28 weeks gestation to coincide with existing routine anaemia blood tests. It was assumed that no new syphilis infection could occur between this screen and delivery.	No data could be found on the incidence of syphilis or the impact of a new syphilis infection that late in pregnancy. Timing of repeat screen based on expert advice – and is hypothetical as repeat screening is not current practice.
No women undergo a repeat screen in the current care pathway (i.e. the single screening strategy).	Following expert advice that few high-risk women receive repeat screening at present. Lack of data around uptake of repeat screening and pregnancy outcomes for low risk vs. high risk women.

Table S2. Pregnancy outcomes - parameter inputs for decision tree comparing universal repeatscreening of syphilis in late pregnancy with single screening

Parameter	Baseline value	Low	High	Note
Pregnant women with no s	syphilis			
IUFD	0.004	0.003	0.005	Tables S3-S5
Preterm delivery	0.075	0.058	0.097	Tables S3-S5
Neonatal death	0.002	0.001	0.003	Tables S3-S5
Congenital syphilis	0.000	-	-	Assumption
Pregnant women with sypl	nilis diagnosed and	d treated <28	3 weeks	
IUFD	0.005	0.002	0.012	Tables S3-S5
Preterm delivery	0.079	0.042	0.143	Tables S3-S5
Neonatal death	0.003	0.001	0.014	Tables S3-S5
Congenital syphilis	0.011	0.008	0.016	Tables S3-S5
Pregnant women with syph	nilis diagnosed and	d treated ≥28	3 weeks	
IUFD	0.023	0.018	0.028	Tables S3-S5
Preterm delivery	0.183	0.119	0.275	Tables S3-S5
Neonatal death	0.013	0.005	0.032	Tables S3-S5
Congenital syphilis	0.038 ¹	0.029	0.047	Tables S3-S5
Pregnant women with syph	nilis not diagnosed	or treated		
IUFD	0.028	0.023	0.033	Tables S3-S5
Preterm delivery	0.241	0.188	0.305	Tables S3-S5
Neonatal death	0.014	0.009	0.022	Tables S3-S5
Congenital syphilis	0.034 ¹	0.026	0.042	Tables S3-S5
Pregnant women infected	with syphilis in pro	egnancy and	diagnosed and	d treated in 3 rd trimester
IUFD	0.006	0.002	0.013	Assumed to have same
Preterm delivery	0.071	0.038	0.127	risk as women
Neonatal death	0.003	0.001	0.015	diagnosed and treated for syphilis infection in
Congenital syphilis	0.010	0.007	0.014	1 st trimester.
Pregnant women infected	with syphilis durin	ig pregnancy	not diagnosed	d or treated
IUFD	0.028	0.023	0.033	Assumed to have same
Preterm delivery	0.241	0.188	0.305	risk as women with
Neonatal death	0.014	0.009	0.022	syphilis not diagnosed or treated. Estimate based
Congenital syphilis	0.500	0.250	0.750	on expert opinion.

IUFD, intrauterine foetal demise. Low and high values are based on the 95% confidence intervals (CIs) from the meta-analysis Qin *et al.* [2] adjusted to the UK setting in the same way as the baseline values (See **Tables S3-S5**).

¹The probability of congenital syphilis in women with syphilis is higher in women treated at \geq 28 weeks gestation than in women receiving no treatment. This is because estimates are from a meta-

analysis which combined data from 15 and 33 studies respectively to estimate risk and both estimates have wide, overlapping confidence intervals.

Table S3. Pregnancy outcome data taken from published large meta-analysis of international studies [2]

			Syphilis infection at time of conception					s infection egnancy
		а	b	с	d	е	f	g
Pregnancy outcome	Women with no syphilis	First screen + treatment 1 st trimester	First screen + treatment 2 nd trimester	First screen + treatment 1/2 nd trimester	First screen + treatment 3 rd trimester	No treatment	Repeat screen + treatment 3 rd trimester	No treatment
Congenital syphilis	0.0%	10.4%	17.6%	12.1%	40.6%	36.0%	10.4%	50%
Preterm delivery	7.2%	6.8%	10.1%	7.6%	17.6%	23.2%	6.8%	23.2%
IUFD (stillbirth)	3.7%	5.3%	4.2%	5.0%	21.3%	26.4%	5.3%	26.4%
Neonatal death	2.0%	3.8%	3.0%	3.6%	15.1%	16.2%	3.8%	16.2%

These data are from a systematic review and meta-analysis which measured pregnancy outcomes in women with and without syphilis (Qin *et al.* [2]). Each estimate is an average calculated by combining data from 2-33 different studies.

The risk of neonatal death was reported for the whole of pregnancy but was not calculated separately for treatment in each pregnancy trimester. For the model, the risk of intrauterine fetal demise (IUFD) in each trimester compared to the overall risk in pregnancy was used to estimate the risk of neonatal death in each trimester compared to the overall risk in pregnancy.

Column c, the risk of pregnancy outcomes if syphilis is diagnosed and treated in the 1st or 2nd trimester, was calculated using data from the 1st and 2nd trimesters (column a and b) and using UK data to calculate the proportion of women first attending antenatal care in their 1st or 2nd trimester (75.9% and 24.1% respectively). For example, the risk of congenital syphilis (CS) was calculated as follows: (0.759*0.104) + (0.241*0.176) = 0.121.

Column e: no treatment group due to a false negative test result. The probability of CS in women with syphilis is higher in women treated in 3rd trimester (column d) than in women receiving no treatment (column e). This is because estimates are from a meta-analysis which combined data from 15 and 33 studies respectively to estimate risk and both estimates have wide, overlapping confidence intervals.

Column f: women infected with syphilis during pregnancy but diagnosed and treated at their repeat screen (in third trimester) are assumed to have the same risk of adverse pregnancy outcomes as women who are diagnosed and treated in their first pregnancy trimester (column a) (from expert opinion).

Column g: the risk of preterm delivery, IUFD and neonatal death is assumed to be the same as for women who have syphilis at conception but who are not treated in pregnancy (column e). However, the risk of CS is estimated as 50%, since the risk is known to be high in primary infection (from expert opinion).

The risk of adverse pregnancy outcomes in women with no syphilis in the meta-analysis data (Qin *et al*) [2] were considerably higher than the numbers seen in pregnant women in the UK. The risk of CS in women with syphilis was also considerably higher in the meta-analysis results than seen in the UK [3,4]. Therefore, these inputs were adjusted to the UK settings (See **Table S4**).

Pregnancy outcome	Meta-analysis data [2]	UK data [n/N]	UK vs. meta-analysis	UK data reference
	Α	В	C	
Women with no syphilis				
Preterm delivery	7.2%	7.485% [57,079/762,594]	104.0%	Table S10
IUFD (stillbirth)	3.7%	$0.393\% [3.93/1000]^{1}$	10.6%	[5]
Neonatal death	2.0%	$0.172\% [1.72/1000]^{1}$	8.6%	[5]
Women with syphilis				
Congenital syphilis (any trimester)	13.7%	1.28% [3.4/266] ²	9.4%	[3,4]

Table S4. Comparing the risk of adverse pregnancy outcomes in meta-analysis with risk observed in the UK in order to scale meta-analysis data

¹The most recent data on pregnancy outcomes from the UK were from 2016 when the total number of pregnancies in the UK was 780,043 [5]. Pregnancy outcomes reported from the UK as a whole are used for the no syphilis group.

² Based on the numbers in our model, we would expect at total of 266 women in 2017/18 to have syphilis in pregnancy i.e. 254 women at the start of pregnancy [0.00035*725,891] plus 12 women infected during pregnancy [0.000017*725,637].

No data on the risk of the different pregnancy outcomes during each trimester were available from the UK. Therefore, the difference in overall risk in pregnancy between the UK and the metanalysis data was used to adjust data from the meta-analysis to calculate the risk of outcomes in each trimester for women in the UK. The calculated risks, used in the model, are presented in **Table S5** and an example of how they were calculated is included in the **Table S5** footnotes.

			Becomes infected during pregnancy					
Pregnancy outcome	Women with no syphilis	First screen + treatment 1 st trimester	First screen + treatment 2 nd trimester	First screen + treatment 1/2nd trimester	First screen + treatment 3rd trimester	No treatment	Repeat screen + treatment 3rd trimester	No treatment
Congenital syphilis	0.0%	0.97%	1.65%	1.14%	3.80%	3.37%	0.97%	50.0%
Preterm delivery	7.48%	7.07%	10.50%	7.90%	18.03%	24.12%	7.07%	24.12%
IUFD (stillbirth)	0.39%	0.56%	0.45%	0.53%	2.26%	2.80%	0.56%	2.80%
Neonatal death	0.17%	0.32%	0.26%	0.31%	1.30%	1.39%	0.32%	1.39%

Table S5. Pregnancy outcome data used in the model – adjusted from published large meta-analysis of international studies [2] to reflect UK risks

These numbers were calculated using data from a meta-analysis (**Table S3**) adjusted by the difference in the (overall) risk of pregnancy outcomes between the UK and the meta-analysis (**Table S4**, column C).

For example, the risk of congenital syphilis (CS) in women treated for syphilis in the $1^{st}/2^{nd}$ trimester (1.14%) was calculated as follows: (0.121*0.094) = 0.0114 i.e. the risk of CS in the $1^{st}/2^{nd}$ trimester from the meta-analysis (**Table S3**, column C) multiplied by the proportional in of risk of CS in pregnancy in the UK vs. the meta-analysis (**Table S4**, column C).

The published 95% confidence intervals were adjusted in the same way to calculate the low and high values used in the sensitivity analysis.

Table S6. Overall number of women screened for syphilis in pregnancy, 2017/18

Country	Total number of deliveries	Estimated number screened	Reference
England	626,203	623,698	[36]
Northern Ireland	23,045	23,038	[38]
Scotland	51,197	50,992	[39]
Wales	28,361	28,248	[40]
UK total	728,806	725,976	

In England, Wales and Scotland, these data exclude women giving birth at home or in non-NHS hospitals.

Screening uptake in 2017/2018 for England, Wales and Scotland was estimated as 99.6% i.e. the same as uptake in England in 2016/2017 [15].

The uptake of screening in 2017/2018 for Northern Ireland was 99.97%, based on data collected by Public Health Agency Northern Ireland 2017/2018.

	<12 w	<12 weeks		12-28 weeks		≥28 weeks		With data	Tatal	Reference	
UK country	n	%	n	%	n	%	 No data 	available	Total	Reference	
England	299,634	70.1%	103,137	24.1%	24,935	5.8%	~200,000	427,706	-	[6]	
Northern Ireland	15,069	65.4%	7,607	33.0%	365	1.6%	4	23,041	23,045	[7]	
Scotland	42,840	84.2%	5,876	11.5%	2,165	4.3%	316	50,881	51,197	[8]	
Wales	22,878	82.2%	4,226	15.2%	745	2.7%	512	27,849	28,361	[9]	
UK total	380,421	71.8%	120,846	22.8%	28,210	5.3%		529,477			

Table S7. Gestational week at first antenatal care attendance – by UK country

All data are for year 2017/18. The SASS study [3] found that in women screening positive for syphilis, 6.4% (81/1271) had their first antenatal attendance at 27 weeks or later. These data were used to calculate pregnancy outcomes and the percentage of women receiving a first syphilis screen before 28 weeks gestation (94.7% i.e. 501,267/529,477).

Table S8. Calculating the cost per antenatal syphilis screen

Activity	Cost per item (£)	Proportion with cost	Average cost/person	Notes
			(£)	
Blood sample collection	0.23	1.00	0.23	Includes only equipment costs. Syphilis screening is performed at the same time as other antenatal screening tests – and therefore does not incur additional staff time.
Laboratory testing (higher cost)	16.50	0.50	8.25	Price quoted in London Sexual Health full STI screen tariff [10].
Laboratory testing (lower cost)	9.00	0.50	4.50	Price quoted by laboratory manager in Leeds. This is the price charged per screen. It covers consumables, internal quality control (IQC), external quality assessment (EQA), laboratory staff time, and overheads. It accounts for the ratio of negative (which require only one test), positive (which require confirmatory work) test results.
Input from multi-disciplinary team	37.50	0.002	0.08	Estimate 1/500 women require 30 minutes input from the MDT based on expert opinion.
Reference laboratory testing	40.00	0.003	0.10	Estimate 1/400 samples sent to reference laboratory for confirmatory testing based on England's central reference lab receiving ~1300 samples/year (personal communication with laboratory manager).
Repeat test blood collection	3.86	0.01	0.04	1/100 women require a repeat test due to inconclusive test results. This cost is taken from London Sexual Health full STI screen tariff [10].
Laboratory testing (higher cost)	16.50	0.005	0.08	Repeat test due to inconclusive test result from first assay.
Laboratory testing (lower cost)	9.00	0.005	0.05	Repeat test due to inconclusive test result from first assay.
Referral to sexual health clinic	56.60	0.0006	0.04	Women with positive result for antibodies are referred to Sexual Health Clinic for sexual history and risk assessment. Cost based on a 30-minute appointment with a consultant plus 5 mins of receptionist time (staff costs taken from PSSRU 2017/18 [11]). Proportion taken from SASS study [3] which found 607/961,494 women had positive antibody result but did not then require treatment.
Total			13.36	

Footnote: A 50:50 split between the higher and lower costs for laboratory tests was used. The cost of a repeat screen was assumed to be the same as the cost of a first screen since in both cases, samples would be taken at a routine antenatal appointment when other blood tests are performed, i.e. HIV and hepatitis B screening at first screen and routine anaemia blood tests at 28 weeks gestation.

Table S9. Calculating the cost of treatment and management of women diagnosed with syphilis in pregnancy

Activity	Cost per	Notes
	woman (£)	
STI Intervention C -	262.34	Cost taken from the London Integrated Sexual Health Tariff 2017/18 which includes 5 visits to clinic
Management of reactive		for treatment with penicillin regimen appropriate for the stage of infection [1,10].
treponemal serology		In pregnant women diagnosed in the first trimester, all 5 visits would occur before delivery, in women diagnosed in final trimester, 3/5 visits would occur before delivery and 2 after delivery (personal communication with senior sexual health consultant).
Additional cost at 1 st visit	16.50	Additional cost due to patient being seen by consultant doctor instead of by doctor/nurse mix [11].
Additional cost at 2 nd visit	8.25	Additional cost due to patient being seen by consultant doctor instead of by doctor/nurse mix [11].
Additional cost at 5 th visit	27.00	Additional cost due to patient being seen by consultant doctor instead of by doctor/nurse mix [11].
Total	314.09	

There would be no change to the staff grade (from the tariff) at the 3rd or 4th visit, when the patient would be seen by a nurse.

This cost was calculated based on expert opinion from a senior consultant in sexual health.

≤ Country	≤33 weeks	;	34-36 weeks		>36 weeks	5	No data	With data	Total	Ref	Notes	
country	n	%	n	%	n	%		available	Total	Nei		
England	13,846	2.1%	35,533	5.4%	607,972	92.5%		657,351	-	[19]	2014 data	
Northern Ireland	470	2.0%	1,385	6.0%	21,190	92.0%	0	23,045	23,045	[7]	2017/18 data	
Scotland	868	1.7%	2,444	4.9%	46,791	93.4%	207	50,103	50,310	[8]	2017/18 data	
Wales	723	2.3%	1,810	5.6%	29,562	92.1%	141	32,095	32,236	[20]	2017 data	
UK total	15,907	2.1%	41,172	5.4%	705,515	92.5%		762,594				

Table S10. Gestational week at delivery (used for calculating delivery costs and estimating pregnancy outcomes)

Table S11. Calculating the average healthcare costs associated with a neonatal death

Activity	Resource/ Activity	Quantity	Cost per unit	Total cost	Ref	Notes:
Cost of IUFD	-	-	-	£4,356.80	[12]	
Hospital stay	Day	3	£483.00	£1,449.00	[1,13]	Based on NHS tariff for Paediatric Major Infections with CC Score 0 - HRG code PW16E.
Total cost				£5,805.80		

The cost of neonatal death is calculated using the cost of intrauterine fetal demise (IUFD), which includes the cost of post-mortem, parental counselling and a subsequent pregnancy, plus an additional 3-days in a paediatric intensive care unit for the neonate. Three days hospital stay is an estimate based on expert opinion.

Table S12. Calculating the cost of testing for syphilis in neonates with clinical signs of congenital syphilis (CS)

Activity	Num	ber	Resource	Resource/	Quantity	Cost per	Cost per	Ref	Notes
	At birth	After birth	type	Activity	/minutes	unit/hour (£)	neonate (£)		
Clinical assessment for signs of CS	1		Staff time	Consultant paediatrician	30	108.00	54.00	[11]	
Review of syphilis test results		8	Staff time	Consultant paediatrician	10 per review	108.00	144.00	[11]	
RPR/VDRL blood test	1	4	Staff time	Blood taken by nurse (band 6)	10 per test	45.00	37.50	[11]	Test at birth, 1, 3, 6 and 12 months.
IgM EIA blood test	1	2	Staff time	Blood taken by nurse	10 per test	45.00	22.50	[11]	Test at birth, 1 and 3 months.
Syphilis blood tests (as above)	2	6	Diagnostics	Laboratory tests	5 (3 combined + 2 single)	12.75	63.75		Same cost if both tests are performed or only RPR/VDRL blood test performed.
Blood tests: full blood count, liver function, electrolytes	1		Staff time	Blood taken by nurse	10	45.00	7.50	[11]	
Blood tests (as above)	1		Diagnostics	Laboratory tests	1	20.00	20.00		Estimate
Lumbar puncture (white blood cell, protein, RPR, TPPA)	1		Staff time	Paediatric registrar	45	43.00	32.25	[11]	
Blood tests (as above)	1		Diagnostics	Laboratory tests	1	20.00	20.00		Estimate
X-ray of long bones	1		Staff time	Consultant Radiographer	30	93.00	46.50	[11]	Based on cost of Band 8c Radiographer

Continued over the page.

Table S12 Continued from previous page.

Activity	Nur	nber	Resource	Resource/	Quantity	Cost per	Cost per	Ref	Notes
	At birth	After birth	type	Activity	/minutes	unit/hour (£)	neonate (£)		
Chest x-ray	1		Staff time	Consultant Radiographer	30	93.00	46.50	[11]	Based on cost of Band 8c Radiographer
X-ray film	1		Diagnostics	Diagnostic tests	2	25.00	50.00	[14]	
Ophthalmic assessment	1		Staff time	Consultant Ophthalmologist	30	108.00	54.00	[11]	
Audiology review	1		Staff time	Audiologist (Associate specialist)	10	105.00	17.50	[11]	
Sample taken for microscopy/PCR	1		Staff time	Nurse (band 6)	10	45.00	7.50	[11]	
Dark ground microscopy and PCR for <i>T. pallidum</i>	1		Diagnostics	Laboratory tests	1	20.00	20.00		Estimate
Results review and liaison with sexual health team	1		Staff time	Consultant paediatrician	60	108.00	108.00	[11]	
Total cost							751.50		

RPR/VDRL, rapid plasma reagent/venereal disease research lab test. Detailed testing protocol was obtained from Clinical Guidelines [1] and expert opinion.

Table S13. Calculating the cost of treating neonates with congenital syphilis (CS)

Activity	Ν	Resource type	Resource/ Activity	Unit	Cost per unit (£)	Cost per neonate (£)	Reference	Notes
Neonates with signs	of CS at o	delivery (40%)						
Treatment for CS	23	Medication	Penicillin (dose 30mg/kg)	105mg dose	3.00 /600mg vial	12.08	[1,15,16]	Dose calculated using average birthweight of 3.5kg.
Treatment for CS	23	Medication	Glucose 5% or sodium chloride 0.9%	Infusion bag	2.14	49.22	[1,15,16]	Standard sized infusion bags are used with the surplus discarded.
Hospital stay	10	Tariff cost	Hospital stay	Days	721.00	7,210.00	[1,13,17]	Based on NHS tariff for Neonatal Diagnoses with CC Score 0 - HRG code PB04D.
Neonates with signs	of CS day	/s/weeks after	delivery (60%)					
Treatment for CS	30	Medication	Penicillin (dose 30mg/kg)	123.75mg dose	3.00 /600mg vial	18.56	[1,15,16]	Dose calculated using average weight at 1 month of 4.125kg.
Treatment for CS	30	Medication	Glucose 5% or sodium chloride 0.9%	Infusion bag	2.14	64.20	[1,15,16]	Standard sized infusion bags are used with the surplus discarded.
Hospital stay	10	Tariff cost	Hospital stay	Days	483.00	4,830.00	[1,13,17]	Based on NHS tariff for Paediatric Major Infections with CC Score 0 - HRG code PW16E.
Total cost of treating	g neonat	es with CS (bas	ed on 40%/60% split)			5,856.18		
Total cost of testing	and trea	ting neonates	with clinical signs of CS			6,607.68		

CS, congenital syphilis. Clinical guidelines recommend that treatment is given every 12 hours (for infants ≤7 days of age) and every 8 hours (for infants >7 days of age) for a total of 10 days with treatment typically starting on the day of delivery.

Table S14. Calculating the cost of neonate screening in infants born to mothers treated for syphili	s in pregnancy
---	----------------

Activity	Nur	nber	Resource	Resource/	Quantity/	Cost per	Cost per	Ref	Notes
	At birth	After birth	type	Activity	minutes	unit/hour (£)	neonate (£)		
Clinical assessment for signs of CS	1		Staff time	Consultant paediatrician	30	108.00	54.00	[11]	
Review of test results		6	Staff time	Consultant paediatrician	10 per review	108.00	108.00	[11]	
RPR/VDRL blood test	1	2	Staff time	Blood taken by nurse	10 per test	45.00	22.50	[11]	Tests every three months until RPR is
IgM EIA blood test	1	2	Staff time	Blood taken by nurse	10 per test	45.00	22.50	[11]	negative (this usually occurs by six months). Cost based on band 6
Syphilis blood tests (as above)	2	4	Diagnostics	Laboratory tests	3 sets of tests	12.75	38.25	[10]	nurse. Based on average combined cost for tests.
Total cost							£245.25		

CS, congenital syphilis; IgM EIA, immunoglobulin M enzyme immunoassay; RPR/VDRL, rapid plasma reagent/venereal disease research lab test.

Table S15. Long-term health care and social care costs associated with congenital syphilis (CS) – results of the model comparing universal repeat screening of syphilis in late pregnancy with single screening

	Short-term costs [Antenatal + postnatal]	Long-term costs ¹	Lifetime costs [short + long- term]	Total QALYs
Single screen	£1,777,469,008	£5,754,176	£1,783,223,184	19,464,817
Universal repeat screen	£1,787,355,870	£2,160,086	£1,789,515,957	19,464,869
Difference	£9,886,863	-£3,594,090	£6,292,773	52.2
ICER				£120,494
DSA: No discounting of util	ities			
Single screen	£1,777,469,008	£5,754,176	£1,783,223,184	58,444,492
Universal repeat screen	£1,787,355,870	£2,160,086	£1,789,515,957	58,444,684
Difference	£9,886,863	-£3,594,090	£6,292,773	192.3
ICER				£32,716
DSA: 6% discounting of uti	lities			
Single screen	£1,777,469,008	£5,754,176	£1,783,223,184	11,948,666
Universal repeat screen	£1,787,355,870	£2,160,086	£1,789,515,957	11,948,686
Difference	£9,886,863	-£3,594,090	£6,292,773	30.6
ICER				£205,600

DSA, deterministic sensitivity analysis; ICER, Incremental cost-effectiveness ratio. Lifetime costs and utilities were discounted at 3.5% unless otherwise stated. Data presented are for all women screened for syphilis in one year (n=725,891).

¹Additional lifetime health and social care costs for individuals born with CS (£651,387 per individual) - adapted from a study of lifetime costs of cerebral palsy in Denmark [18]. The social care costs include specialised schooling, and after school care, support to parents, residential institutions, supervised workshops, day centre, and other adult support services.

 Table S16. Clinical outcomes for Scenario 3 (0.00012 probability of syphilis infection in pregnancy)

Strategy	Syphilis antenatal screens	Women treated for syphilis	False positive screens	Intrauterine fetal demise	Preterm deliveries	Neonatal deaths	Congenital syphilis
Existing: single screen	725,891	1,709	1,451	2,906.1	54,240	1,447	43.2
Alternative: repeat screen	1,411,696	3,163	2,823	2,904.3	54,226	1,446	4.2
Difference	685,805	1,455	1,371	-1.8	-13	-0.9	-39.0

Table S17. Cost outcomes for Scenario 3 (0.00012 probability of syphilis infection in pregnancy)

Cost	Total	Antenatal screening	Syphilis treatment (in pregnant women)	Perinatal costs	
Existing: single screen	£ 1,777,764,124	£ 9,697,904	£ 536,669	£ 1,767,529,551	
Alternative: repeat screen	£ 1,787,402,601	£ 18,860,259	£ 993,521	£ 1,767,548,821	
Difference	£ 9,638,476	£ 9,162,355	£ 456,852	£ 19,270	

Table S18. Requirements to prevent one outcome for Scenario 3 (0.00012 probability of syphilis infection in pregnancy)

Outcome	Cost	Women screened in third trimester	Women treated for syphilis – TP and FP	Additional false positives
Congenital syphilis	£247,284	17,595	37	35
IUFD	£5,332,625	379,431	805	759
Neonatal death	£11,063,507	787,200	1,670	1,574

TP, True positive; FP, False positive

 Table S19. Short and long-term cost outcomes for Scenario 3 (higher syphilis incidence in pregnancy)

Syphilis incidence (new infections between screens) Probability (%)		Screening Strategy	Short-term costs	Pregnancy outcomes			Short-term cost per CS case	Lifetime health and social care costs	
			-	IUFD	Preterm	Neonatal death	Congenital syphilis	prevented	ICER
0.00003	(0.003)	Single	£1,777,506,256	2,904.6	54,229.9	1,446.6	13.2		
		Repeat	£1,787,361,768	2,904.1	54,226.5	1,446.4	3.4		
		Difference	£9,855,513	-0.5	-3.4	-0.2	-9.7	£1,011,791	£38,140
0.00004	(0.004)	Single	£1,777,534,908	2,904.8	54,231.0	1,446.7	16.5		
		Repeat	£1,787,366,305	2,904.1	54,226.4	1,446.4	3.5		
		Difference	£9,831,398	-0.6	-4.5	-0.3	-13.0	£756,892	£11,171
0.00005	(0.005)	Single	£1,777,563,560	2,904.9	54,232.1	1,446.8	19.8		
		Repeat	£1,787,370,842	2,904.2	54,226.4	1,446.4	3.6		
		Difference	£9,807,283	-0.8	-5.7	-0.4	-16.2	£603,983	Cost saving
0.00006	(0.006)	Single	£1,777,592,212	2,905.1	54,233.1	1,446.9	23.2		
		Repeat	£1,787,375,379	2,904.2	54,226.4	1,446.4	3.7		
		Difference	£9,783,167	-0.9	-6.8	-0.4	-19.5	£502,056	Cost saving
0.00007	(0.007)	Single	£1,777,620,864	2,905.2	54,234.2	1,446.9	26.5		
		Repeat	£1,787,379,916	2,904.2	54,226.4	1,446.4	3.8		
		Difference	£9,759,052	-1.1	-7.9	-0.5	-22.7	£429,258	Cost saving
0.00008	(0.008)	Single	£1,777,649,516	2,905.4	54,235.3	1,447.0	29.9		
	. ,	Repeat	£1,787,384,453	2,904.2	, 54,226.3	1,446.4	3.9		
		Difference	£9,734,937	-1.2	-9.0	-0.6	-26.0	£374,662	Cost saving

Table continued over the page.

27

Table S19. Continued from previous page.

between screens)		Screening Strategy	Short-term costs	Pregnancy outcomes Short-term costs				Short-term cost per CS case	Lifetime health and social care costs
			-	IUFD	Preterm	Neonatal death	Congenital syphilis	prevented	ICER
0.00009	(0.009)	Single	£1,777,678,168	2,905.6	54,236.4	1,447.1	33.2		
		Repeat	£1,787,388,990	2,904.2	54,226.3	1,446.4	4.0		
		Difference	£9,710,822	-1.4	-10.1	-0.7	-29.2	£332,201	Cost saving
0.0001	(0.01)	Single	£1,777,706,820	2,905.7	54,237.5	1,447.2	36.5		
		Repeat	£1,787,393,527	2,904.2	54,226.3	1,446.4	4.1		
		Difference	£9,686,707	-1.5	-11.2	-0.7	-32.5	£298,234	Cost saving
0.00011	(0.011)	Single	£1,777,735,472	2,905.9	54,238.6	1,447.3	39.9		
		Repeat	£1,787,398,064	2,904.3	54,226.3	1,446.5	4.1		
		Difference	£9,662,592	-1.7	-12.4	-0.8	-35.7	£270,443	Cost saving
0.00012	(0.012)	Single	£1,777,764,124	2,906.1	54,239.7	1,447.3	43.2		
		Repeat	£1,787,402,601	2,904.3	54,226.2	1,446.5	4.2		
		Difference	£9,638,476	-1.8	-13.5	-0.9	-39.0	£247,284	Cost saving

CS, congenital syphilis; ICER, IUFD, Intrauterine foetal demise; ICER, Incremental cost-effectiveness ratio. Lifetime costs and utilities were discounted at 3.5%.

¹Lifetime health and social care costs adapted from a study of lifetime costs of cerebral palsy in Denmark [18]. The social care costs include specialised schooling, and after school care, support to parents, residential institutions, supervised workshops, day centre, and other adult support services.

28

Table S20. Cost per screen needed to meet NICE ICER thresholds (Scenario 7)

Threshold of interest	Per screen cost required to achieve threshold	Incremental cost- effectiveness ratio (ICER)	Additional short-term cost (repeat screen vs. single screen)	Cost per CS case avoided (short-term cost)
Long-term health and social care co	sts and utilities			
£100k ICER threshold	£11.79	£99,877.04	£8,810,149	£1,596,738
£30k ICER threshold	£6.46	£29,884.61	£5,154,808	£934,250
£20k ICER threshold	£5.70	£19,904.45	£4,633,596	£839,786
Per screen cost half the baseline	£6.68	£32,773.60	£5,305,685	£961,594
value (used in DSA)				

CS, congenital syphilis; DSA, deterministic sensitivity analysis. ICERs were calculated using the additional lifetime health and social care cost of CS (£651,387) as used in Scenario 1 adapted from a study of lifetime costs of cerebral palsy in Denmark [18]. Per screen cost was calculated to the nearest penny. Lifetime costs and utilities were discounted at 3.5%.

References

- 1 Kingston M, French P, Higgins S, *et al.* UK national guidelines on the management of syphilis 2015. *Int J STD AIDS* 2016;**27**:421–46. doi:10.1177/0956462415624059
- 2 Qin J, Yang T, Xiao S, *et al.* Reported Estimates of Adverse Pregnancy Outcomes among Women with and without Syphilis: A Systematic Review and Meta-Analysis. *PLoS ONE* 2014;**9**:e102203. doi:10.1371/journal.pone.0102203
- 3 Townsend CL, Francis K, Peckham CS, *et al.* Syphilis screening in pregnancy in the United Kingdom, 2010-2011: a national surveillance study. *BJOG* 2017;**124**:79–86. doi:10.1111/1471-0528.14053
- Simms I, Tookey PA, Goh BT, et al. The incidence of congenital syphilis in the United Kingdom:
 February 2010 to January 2015. BJOG 2017;124:72–7. doi:10.1111/1471-0528.13950
- 5 MBRRACE-UK. Perinatal Mortality Surveillance Report. UK Perinatal Deaths for Births from January to December 2016. www.npeu.ox.ac.uk (Accessed 12 Mar 2020).
- 6 NHS Digital. NHS Maternity Statistics, England 2017-18. 2018. https://digital.nhs.uk/data-andinformation/publications/statistical/nhs-maternity-statistics/2017-18 (Accessed 12 Mar 2020).
- 7 Northern Ireland Maternity System data provided on request from the Public Health Agency (Health Intelligence Unit), Northern Ireland. July 2018.
- 8 Data provided on request by ISD NHS Scotland's Population Health: Maternity, Sexual Health and Unintentional Injuries Team. July 2018.
- 9 Data provided on request by the Welsh Government's Knowledge and Analytic Services, Health
 & Social Services Group. July 2018.
- 10 Pathway Analytics. Integrated Sexual Health Tariff London ISHT 2017/2018. https://www.pathwayanalytics.com/ (Accessed 12 Mar 2020).
- 11 Curtis, L. & Burns, A. (2018) Unit Costs of Health and Social Care 2018, Personal Social Services Research Unit, University of Kent, Canterbury. https://www.pssru.ac.uk/project-pages/unitcosts/unit-costs-2018/ (Accessed 12 Mar 2020).

- 12 Campbell H, Kurinczuk J, Heazell A, *et al.* Healthcare and wider societal implications of stillbirth: a population-based cost-of-illness study. *BJOG: Int J Obstet Gy* 2018;**125**:108–17. doi:10.1111/1471-0528.14972
- 13 NHS Improvement. 2017/18 National Prices and National tariff workbook. 2017. https://improvement.nhs.uk/resources/national-tariff-1719/ (Accessed 12 Mar 2020).
- 14 NHS Improvement. Non mandatory currencies and prices 2017/2018. 2017. https://improvement.nhs.uk/resources/national-tariff-1719/ (Accessed 12 Mar 2020).
- 15 BNF: British National Formulary NICE. https://bnf.nice.org.uk/ (Accessed 12 Mar 2020).
- 16 WHO Child Grown Standards. http://www.who.int/childgrowth/standards/weight_for_age/en/ (Accessed 12 Mar 2020).
- 17 Owusu-Edusei KJ, Introcaso CE, Chesson HW. Hospitalization Cost of Congenital Syphilis Diagnosis From Insurance Claims Data in the United States. *Sexually Transmitted Diseases* 2013;40:226. doi:10.1097/OLQ.0b013e31827c5b9f
- 18 Kruse M, Michelsen SI, Flachs EM, et al. Lifetime costs of cerebral palsy. Developmental Medicine & Child Neurology 2009;51:622–8. doi:10.1111/j.1469-8749.2008.03190.x
- 19 ONS. Analysis of population estimates tool Office for National Statistics. 2019. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/population estimates/datasets/analysisofpopulationestimatestool (Accessed 12 Mar 2020).
- 20 Welsh Government, Statistics for Wales. Maternity statistics, Wales 2017-18. Welsh Government 2018. https://gov.wales/maternity-statistics-april-2017-march-2018 (Accessed 12 Mar 2020).